A machine learning model based on CHAT-23 for early screening of autism in Chinese children

基于CHAT-23的机器学习模型用于中国儿童自闭症的早期筛查

阅读:1

Abstract

INTRODUCTION: Autism spectrum disorder (ASD) is a neurodevelopmental condition that significantly impacts the mental, emotional, and social development of children. Early screening for ASD typically involves the use of a series of questionnaires. With answers to these questionnaires, healthcare professionals can identify whether a child is at risk for developing ASD and refer them for further evaluation and diagnosis. CHAT-23 is an effective and widely used screening test in China for the early screening of ASD, which contains 23 different kinds of questions. METHODS: We have collected clinical data from Wuxi, China. All the questions of CHAT-23 are regarded as different kinds of features for building machine learning models. We introduce machine learning methods into ASD screening, using the Max-Relevance and Min-Redundancy (mRMR) feature selection method to analyze the most important questions among all 23 from the collected CHAT-23 questionnaires. Seven mainstream supervised machine learning models were built and experiments were conducted. RESULTS: Among the seven supervised machine learning models evaluated, the best-performing model achieved a sensitivity of 0.909 and a specificity of 0.922 when the number of features was reduced to 9. This demonstrates the model's ability to accurately identify children for ASD with high precision, even with a more concise set of features. DISCUSSION: Our study focuses on the health of Chinese children, introducing machine learning methods to provide more accurate and effective early screening tests for autism. This approach not only enhances the early detection of ASD but also helps in refining the CHAT-23 questionnaire by identifying the most relevant questions for the diagnosis process.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。